Details of the Drug Reposition

General Information of This Drug (ID: DM98IXF)

• Drug Name: Triamcinolone (DM98IXF)
• Synonyms: Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
• Therapeutic Class: Antiinflammatory Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

37 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sympathetic ophthalmia	DISD35KW	N.A.	Approved	[1]
Subacute bursitis	DISHKNMU	N.A.	Approved	[1]
Serum sickness	DIS0MRKJ	N.A.	Approved	[1]
Rheumatic heart disease	DISCI8JQ	N.A.	Approved	[1]
Primary cutaneous T-cell lymphoma	DIS35WVW	N.A.	Approved	[1]
Miliary tuberculosis	DIS4AT5W	N.A.	Approved	[1]
Granuloma annulare	DISMOUMI	N.A.	Approved	[1]
Gingival disorder	DISD5M1D	N.A.	Approved	[1]
Exanthem	DISAFOQN	N.A.	Approved	[1]
Erythema multiforme	DISKCLM1	N.A.	Approved	[1]
Epicondylitis	DIS0R2VM	N.A.	Approved	[1]
Disorder of orbital region	DISH0ECJ	N.A.	Approved	[1]
Diamond-Blackfan anemia	DISI2SNW	N.A.	Approved	[1]
Bursitis	DISCF7Y9	N.A.	Approved	[1]
Aspiration pneumonitis	DIS5S4DE	N.A.	Approved	[1]
Acute adrenal insufficiency	DIS66YLV	N.A.	Approved	[1]
Bacterial infection	DIS5QJ9S	1A00-1C4Z	Approved	[1]
Inflammation	DISJUQ5T	1A00-CA43.1	Approved	[1]
Cutaneous candidiasis	DIS2U1JN	1F23.14	Approved	[1]
Mycosis fungoides	DIS62RB8	2B01	Approved	[1]
Autoimmune haemolytic anaemia	DIS7MS3M	3A20	Approved	[1]
Angioedema	DIS90QDN	4A00.15	Approved	[1]
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Approved	[1]
Sarcoidosis	DISE5B8Z	4B20.5	Approved	[1]
Congenital adrenal hyperplasia	DISG873W	5A71.01	Approved	[1]
Addison disease	DIS7HNOH	5A74.0	Approved	[1]
Multiple sclerosis	DISB2WZI	8A40	Approved	[1]
Cerebral edema	DIS4GHSB	8D60.1	Approved	[1]
Seasonal allergic rhinitis	DIS58KQX	CA08.01	Approved	[1]
Severe asthma	DISAVQI3	CA23	Approved	[1]
Crohn disease	DIS2C5Q8	DD70	Approved	[1]
Inflammatory bowel disease	DISGN23E	DD72	Approved	[1]
Skin disease	DISDW8R6	EA00-EM0Z	Approved	[1]
Psoriasis	DIS59VMN	EA90	Approved	[1]
Dermatitis herpetiformis	DIS0TC0G	EB44	Approved	[1]
Alopecia areata	DIS0XXBJ	ED70.2	Approved	[1]
Psoriatic arthritis	DISLWTG2	FA21	Approved	[1]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pemphigus	DISZAZ6M	N.A.	Withdrawn	[2]

8 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Tendinitis	DISS7ANY	N.A.	Discontinued in Phase 3	[3]
Thyroiditis	DISTCV24	N.A.	Discontinued in Phase 3	[4]
Lichen planus	DISRPMMS	N.A.	Discontinued in Phase 3	[5]
Nephrotic syndrome	DISSPSC2	N.A.	Discontinued in Phase 3	[6]
Autoimmune disease	DISORMTM	4A40-4A45	Discontinued in Phase 3	[7]
Giant cell arteritis	DISSP87T	4A44.2	Discontinued in Phase 3	[8]
Seborrhoeic dermatitis	DISNWVJU	EA81	Discontinued in Phase 3	[9]
Ankylosing spondylitis	DISRC6IR	FA92.0	Discontinued in Phase 3	[10]

6 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Exfoliative dermatitis	DISQEWIW	N.A.	Discontinued in Phase 2	[11]
Non-hodgkin lymphoma	DISS2Y8A	2B33.5	Discontinued in Phase 2	[12]
Atopic dermatitis	DISTCP41	EA80	Discontinued in Phase 2	[13]
Contact dermatitis	DISQ3AU0	EK0Z	Discontinued in Phase 2	[14]
Musculoskeletal disorder	DISPPN0O	FA00-FC0Z	Discontinued in Phase 2	[15]
Arthritis	DIST1YEL	FA20	Discontinued in Phase 2	[16]

3 Discontinued in Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Tenosynovitis	DISR5H9R	N.A.	Discontinued in Phase 1	[17]
Humoral hypercalcemia of malignancy	DISQQ62D	N.A.	Discontinued in Phase 1	[18]
Aphthous stomatitis	DISR2T25	N.A.	Discontinued in Phase 1	[19]

8 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Trichinellosis	DISUR2ZW	N.A.	Investigative	[1]
Synovitis	DISW2GPY	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	DISV1LU6	N.A.	Investigative	[1]
Beta-thalassemia major	DISW06BV	N.A.	Investigative	[1]
Acquired thrombocytopenia	DISXH01C	N.A.	Investigative	[1]
Follicular lymphoma	DISVEUR6	2A80	Investigative	[1]
Uveitis	DISV0RYS	9A96.Z	Investigative	[1]
Keloid	DISV09JY	EE60	Investigative	[1]

References

• [1] Triamcinolone FDA Label
• [2] Inflammation Control For Elders: ICE Study
• [3] Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
• [4] A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
• [5] Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
• [6] High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
• [7] Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
• [8] Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study
• [9] Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder
• [10] A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
• [11] Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
• [12] AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
• [13] Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
• [14] Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
• [15] Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
• [16] ClinicalTrials.gov (NCT00033371) Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
• [17] ClinicalTrials.gov (NCT01403285) Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma. U.S. National Institutes of Health.
• [18] Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
• [19] A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer